1-10 of 10
Theodore Karrison
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck

Cherie-Ann O. Nathan, D. Neil Hayes, Theodore Karrison, Olivier Harismendy, José M. Flores, Tara Moore-Medlin, Everett E. Vokes, J. Silvio Gutkind, Prakash Neupane, Glenn Mills, Zoukaa Sargi, Tanguy Seiwert, Juneko Grilley-Olson, Terry Day, Maura Gillison, James L. Wade, Lawrence Feldman, Gautam Jha, Mark Kozloff, Miriam O'Leary, Francis P. Worden, Ezra E.W. Cohen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5040–5048.
https://doi.org/10.1158/1078-0432.CCR-21-4290
Published: 01 December 2022
View article titled, A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
Open the PDF for A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck in another window
Includes: Supplementary data
Journal Articles

Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

Anthony V. Serritella, Daniel Shevrin, Elisabeth I. Heath, James L. Wade, Elia Martinez, Amanda Anderson, Joseph Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M. Stadler, Russell Z. Szmulewitz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1549–1559.
https://doi.org/10.1158/1078-0432.CCR-21-4049
Published: 14 April 2022
View article titled, Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial

Jason J. Luke, Benjamin E. Onderdonk, Sandeep R. Bhave, Theodore Karrison, Jeffrey M. Lemons, Paul Chang, Yuanyuan Zha, Tim Carll, Thomas Krausz, Lei Huang, Carlos Martinez, Linda A. Janisch, Robyn D. Hseu, John W. Moroney, Jyoti D. Patel, Nikolai N. Khodarev, Joseph K. Salama, Patrick A. Ott, Gini F. Fleming, Thomas F. Gajewski, Ralph R. Weichselbaum, Sean P. Pitroda, Steven J. Chmura
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6437–6444.
https://doi.org/10.1158/1078-0432.CCR-20-1790
Published: 15 December 2020
View article titled, Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial
Open the PDF for Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Stepwise development of biomarkers for angiogenic activity with standardized assays for circulating molecules in human subjects

Michael L. Maitland, Emily Kistner, Larry House, Theodore Karrison, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): B84.
Published: 15 August 2014
View article titled, Stepwise development of biomarkers for angiogenic activity with standardized assays for circulating molecules in human subjects
Journal Articles

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Nitin Jain, Emily Curran, Neil M. Iyengar, Ernesto Diaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark H. Kirschbaum, Theodore Karrison, Harry P. Erba, Margaret Green, Xavier Poire, Greg Koval, Kevin Shannon, Poluru L. Reddy, Loren Joseph, Ehab L. Atallah, Philip Dy, Sachdev P. Thomas, Scott E. Smith, L. Austin Doyle, Walter M. Stadler, Richard A. Larson, Wendy Stock, Olatoyosi Odenike
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2): 490–498.
https://doi.org/10.1158/1078-0432.CCR-13-1311
Published: 16 January 2014
View article titled, Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Open the PDF for Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial in another window
Includes: Supplementary data
Journal Articles

Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

Michael L. Maitland, Kristen E. Kasza, Theodore Karrison, Kristin Moshier, Laura Sit, Henry R. Black, Samir D. Undevia, Walter M. Stadler, William J. Elliott, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6250–6257.
https://doi.org/10.1158/1078-0432.CCR-09-0058
Published: 30 September 2009
View article titled, Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
Open the PDF for Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

Christine M. Hartford, Apurva A. Desai, Linda Janisch, Theodore Karrison, Victor M. Rivera, Lori Berk, John W. Loewy, Hedy Kindler, Walter M. Stadler, Heather L. Knowles, Camille Bedrosian, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1428–1434.
https://doi.org/10.1158/1078-0432.CCR-08-2076
Published: 19 February 2009
View article titled, A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
Open the PDF for A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies in another window
Journal Articles

A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer

Walter M. Stadler, Dingcai Cao, Nicholas J. Vogelzang, Christopher W. Ryan, Kristin Hoving, Russell Wright, Theodore Karrison, Everett E. Vokes
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3365–3370.
https://doi.org/10.1158/1078-0432.CCR-03-0404
Published: 24 May 2004
View article titled, A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer
Open the PDF for A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer in another window
Journal Articles

Determination of the Optimal Modulatory Dose of O 6-Benzylguanine in Patients with Surgically Resectable Tumors

M. Eileen Dolan, Mitchell Posner, Theodore Karrison, Jonathan Radosta, Gary Steinberg, Donna Bertucci, Lucky Vujasin, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (8): 2519–2523.
Published: 01 August 2002
View article titled, Determination of the Optimal Modulatory Dose of <em>O</em> <sup>6</sup>-Benzylguanine in Patients with Surgically Resectable Tumors
Open the PDF for Determination of the Optimal Modulatory Dose of <em>O</em> <sup>6</sup>-Benzylguanine in Patients with Surgically Resectable Tumors in another window
Journal Articles

Human Breast Cancer Susceptibility to Paclitaxel Therapy Is Independent of Bcl-2 Expression

Susan M. Poelman, Moses O. Adeyanju, Maria-Antonia Robertson, Wendy M. Recant, Theodore Karrison, Gini F. Fleming, Olufunmilayo I. Olopade, Suzanne D. Conzen
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (10): 4043–4048.
Published: 01 October 2000
View article titled, Human Breast Cancer Susceptibility to Paclitaxel Therapy Is Independent of Bcl-2 Expression
Open the PDF for Human Breast Cancer Susceptibility to Paclitaxel Therapy Is Independent of Bcl-2 Expression in another window